Impact of XDR-TB on treatment outcome of patients with MDR-TB

Abstract number: O187

Tabarsi P., Baghaei P., Marjani M., Amiri M., Masjedi M., Caminero J.

Design: The very limited experience treating patients with extensively drug-resistant tuberculosis (XDR-TB) shows a therapeutic success rate under 50 to 60% and there are not publications regarding the outcome of these patients treated with standardised regimes.

Material and Methods: All MDR-TB patients hospitalised at Masih Daneshvari Hospital in Tehran, Iran during 2004–2007. A drug susceptibility to 13 drugs (included 8 second line drugs – SLD) were performed and a standardised regimen with ofloxacin, cycloserine, prothionamide, and amikacin was administered. Outcome of the patients was studied, comparing between the MDR-TB non XDR-TB and the XDR-TB.

Results: 51 patients were included, 12 with XDR-TB criteria. XDR-TB infection was significantly only associated with age (p = 0.039). The success rate for the 51 total MDR-TB, the 39 MDR-TB non XDR-TB and the 12 XDR-TB patients was 76.5% (39 patients), 87.2% (34 patients) and 41.6% (5 patients), respectively. Resistance to Ofloxacin, Ciprofloxacin, and Amikacin, were found to have statistically significant association with unsuccessful outcome.

Conclusions: In this setting, a standardised SLD regimen produces high treatment success rates in MDR-TB patients unless XDR-TB is present.


Session Details

Date: 16/05/2009
Time: 00:00-00:00
Session name: 19th European Congress of Clinical Microbiology and Infectious Diseases
Location: Helsinki, Finland, 16 - 19 May 2009
Presentation type:
Back to top